MRK vs REPL · P/E 33, rev $65.01B vs $825.7M cap
Merck & Company Inc (MRK) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Rob Davis.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported MRK revenue for 2025-12-31 was $65.01B. Net income was $18.25B. Revenue was up 1.3% from 2024-12-31 to 2025-12-31. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
REPL does not have a complete income-statement cache yet.
MRK currently screens at market cap $285.12B and trailing P/E 32.5. REPL currently screens at market cap $825.7M.
Not investment advice. Open the MRK and REPL stock pages for the full models.
Not investment advice.